Reed's Ruse Reveals He'd Rather Talk Cancer, Not His Name-Tagging Past
When we last sat down with Reed Coombes at TechCrunch Disrupt nearly three years ago, his firm Yosemite was still in its early days. The venture had recently relocated to a new facility and was struggling to find its footing after the post-pandemic tech crash. However, since then, things have changed dramatically. With a team of 17 now operating out of their newly renovated space, Yosemite has become a hub for innovative biotech solutions.
The news is particularly significant given the recent expiration dates of several blockbuster drug patents around the same time. This presents an unprecedented opportunity for innovation and growth in the life sciences sector. For Reed Coombes, the focus has shifted from his past concerns about patent protection to exploring new avenues of research and development. "I didn't expect Yosemite to be moving this fast," he acknowledged, indicating that the team is eager to capitalize on these opportunities.
The incorporation of AI technology into its operations marks a significant shift for Yosemite, which had previously been focused primarily on biotech solutions. Coombes believes that AI will play a major role in driving growth and innovation within the firm. As Yosemite continues to expand and grow, it's likely that we'll see more advancements in this area. For now, Coombes is excited to see where these new opportunities take the team and the company as a whole.